GSTM1 and rectal neoplasm: The aim of the present study was to investigate whether Hb levels at diagnosis can be used (i) as a biomarker of rectal tumour morphology and hence reflect the stage of disease, (ii) to predict rectal cancer response to neoadjuvant treatment, and (iii) to determine long-term cancer specific outcome.